OX40-deficient effector CD8 T cells were previously found to be impaired in expressing Bcl-xL, and forced expression of Bcl-xL into OX40 KO or WT CD8 T cells augmented their survival and anti-tumor activity [3], [29]. The gene discussed is BCL2L1; the disease is neoplasm.